Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2020 December;62(4) > Panminerva Medica 2020 December;62(4):234-43

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

SPECIAL ARTICLE  MULTIPLE MYELOMA IN 2020: STATE OF THE ART (PART I) Freefree

Panminerva Medica 2020 December;62(4):234-43

DOI: 10.23736/S0031-0808.20.04142-7

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?

Massimo MARTINO 1, Annalisa PAVIGLIANITI 1, Massimo GENTILE 2, Giovanni MARTINELLI 3, Claudio CERCHIONE 4

1 Unit of Stem Cell Transplantation and Cellular Therapies, Bianchi-Melacrino-Morelli Hospital, Reggio Calabria, Italy; 2 Unit of Hematology, Hospital of Cosenza, Cosenza, Italy; 3 IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy; 4 Unit of Hematology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy



Multiple myeloma (MM) accounts for about 1.8% of all cancers and slightly over 17% of hematologic malignancies. Despite improvements in outcomes in recent years, currently, there is still no cure for this disease. Although allogeneic stem cell transplantation (Allo-SCT) is a potentially curative treatment, given the armamentarium of highly effective therapeutic options and a pipeline of novel agents, many opinion leaders sustain that there is no longer a role for this approach. Of note, several studies that did not include novel agents reported long-term molecular remissions, and possibly a cure, in a subset of patients after reduced-intensity conditioning/nonmyeloablative (RIC/NM) Allo-SCT. However, there are no current data supporting upfront Allo-SCT. Prospective trials combining the so-called “graft-versus-myeloma” effect and new drugs are an unmet medical need in high-risk patients. Early relapse after first-line treatment, which identifies patients with poor prognosis independently of other prognostic factors, could become a clinical indication.


KEY WORDS: Multiple myeloma; Stem cell transplantation; Transplant

inizio pagina